Daily digest — 2026-09-02

First-mover matters more than usual here: Wave's WVE-003 and PTC's PTC518 are both earlier-stage, so a clean AMT-130 approval buys uniQure a real multi-year head start — once a Huntington's patient gets a one-time AAV infusion, there's no switching later. The external-control strategy is the real story though. FDA reportedly pushed back before coming around, so this reads as a precedent still being negotiated in real time, not a settled template — a green light here would embolden every small-N gene therapy sponsor; a post-approval stumble (Sarepta's the cautionary comp) would make uniQure the counterexample instead. Priority Review is less validation of the science than a compressed timeline for a single-asset story that's had its own FDA whiplash — the shorter clock is the real de-risking event for the stock, not proof the data holds up long-term.

A miss with an asterisk, not a pivot. IFNGS-high response is biologically coherent — interferon signature is literally TYK2's mechanism — so this isn't pure spin like some post-hoc subgroup rescues. But shrinking Phase 3 to biomarker-enriched patients trades a bigger addressable market for a better shot at significance; that's the right call scientifically, wrong one commercially unless a companion diagnostic scales cleanly. Versus BMS's already-approved Sotyktu, Alumis needed a clean topline to differentiate TYK2 in autoimmune beyond psoriasis — it didn't get one. Expect the Street to stay skeptical until FDA blesses the enrichment strategy; a >50% drop doesn't reverse on a CEO's confidence alone. Psoriasis filing is now doing the heavy lifting for the story — good, since it's biomarker-agnostic — but lupus was supposed to be the platform proof point, and that thesis just got smaller.

Beating teriflunomide isn't the same as beating the field's real benchmark — ocrelizumab, natalizumab, the high-efficacy therapies most MS neurologists already reach for first. Still, the safety data are the real story here. Hepatotoxicity has dogged this drug class, including flags on Sanofi's rival tolebrutinib program, so a clean liver readout is a genuine differentiator, not just noise. If remibrutinib's selectivity truly spares the liver, Novartis gets real separation in the BTK race rather than a me-too label. Add this to the existing CSU approval and Novartis is building an actual platform molecule — one asset, multiple indications, shared manufacturing and commercial muscle. The number to watch next: whether that disability-progression trend holds up, since that's what actually shifts prescribing.

Autoantibody degradation goes after a gap FcRn inhibitors like Vyvgart can't close — those broadly dial down IgG, this targets the specific rogue antibodies. If MER511's Graves' data hold, it's a cleaner mechanism story than another B-cell depleter. The structure says Lilly isn't paying for hope: milestone-heavy pricing on preclinical/Phase 1 assets pushes the risk onto Merida's team hitting data, not onto Lilly's balance sheet. $2.88B is reasonable for a validated new modality, rich if MER511 stalls. It slots next to lebrikizumab and mirikizumab without cannibalizing either. The real signal is deal #13 this year — Lilly's recycling GLP-1 cash into next-gen immunology and allergy bets while it still has the war chest to shop early.